ArticleInternational journal of technology assessment in health care2025
Cost-effectiveness analysis of blood cell separators in allogeneic hematopoietic stem cell transplantation: a perspective from the Chinese healthcare system.
Article in International journal of technology assessment in health care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllogeneic hematopoietic stem cell transplantation (HSCT) is essential for the long-term survival of acute leukemia (AL) patients. Peripheral blood stem cell transplantation has become the preferred method due to its lower invasiveness and convenience. The blood cell separator is key for hematopoietic progenitor cell collection, with CD34+ cell collection efficiency (CE) influencing transplant outcomes and healthcare costs. This study compares the cost-effectiveness of two devices, Spectra Optia and COM.TEC apheresis system, to assess their impact on CD34+ cell CE in HSCT.
methodsA decision tree-Markov model was constructed from the perspective of the healthcare system to simulate the 5-year outcomes of 10,000 acute leukemia patients experiencing allogeneic stem cell transplantation. Resource cost differences between two devices were analyzed under two scenarios: minimizing resource consumption (scenario 1) and maximizing CD34+ cell volume (scenario 2). Cost-effectiveness analysis was undertaken combining quality-adjusted life years (QALYs) and total medical costs, with incremental net monetary benefit calculated at predefined willingness-to-pay thresholds.
resultsCompared to COM.TEC, Spectra Optia reduced apheresis times by 1-6 percent and improved the rate of engraftment success by 0.23 percent to 1.82 percent. In scenario 1, the net benefit per patient ranged from $634.85 to $1,260.43, and in scenario 2, the net benefit per patient ranged from $169.62 to $256.65.
conclusionHigher CE of the apheresis system optimizes both healthcare resource consumption and clinical outcomes. In the analysis considering the device price, Spectra Optia achieved cost-effectiveness dominance over COM.TEC at a surgical volume exceeding 121 cases per device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.